ESTRO 2022 - Abstract Book

S898

Abstract book

ESTRO 2022

Fig 1. Privacy preserving distributed dashboard for four public HNSCC datasets

Conclusion An interactive distributed dashboard was deployed through the open source federated privacy-preserving infrastructure, Vantage6. The procedure was developed on four public datasets, then applied on three geographically separated private datasets. Annotating datasets as FAIR data allows researchers to explore and evaluate the case mix through a universal distributed dashboard without breaching confidentiality of patient-level data. This allows institutions to plan collaborations while retaining total control over their own data.

PO-1063 Quality-of-life and perceptions in cancer patients treated with multiple courses of radiotherapy

M. Ahmadsei 1 , S.M. Christ 1 , A. Seiler 1 , E. Vlaskou Badra 1 , J. Willmann 1 , C. Hertler 1 , M. Guckenberger 1

1 University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland

Purpose or Objective Recent advances have transformed cancer into a chronic disease for a growing number of patients. As a consequence quality-of-life (QoL), patient-reported experiences and satisfaction (PRES) and psychological distress are gaining relevance as oncological outcome measures. This analysis reports on QoL and PRES of cancer patients treated with multiple courses of radiotherapy (MRRT) during their long-term disease history. Materials and Methods All patients having received ≥ 5 courses of radiotherapy (RT) between 2011 and 2019 at the Department of Radiation Oncology, University Hospital Zurich, were included into this analysis. A course of radiotherapy was defined as all treatment sessions to one anatomical site under one medical indication. Patient and treatment characteristics were assessed in their medical records. All patients were invited to complete two questionnaires: EORTC QLQ-C30 questionnaire for QOL and a self-created questionnaire evaluating PRES of their treatment with multiple courses of radiotherapy. Results At time of analysis 33 patients, who received ≥ 5 courses (total number of RT courses = 210), were alive. Of those 20 (60%) participated in this study. The most common primary tumor was non-small-cell lung cancer (n=14, 42.4%). The most common sites of irradiation were brain (n=78, 37.1%) and bone metastases (n=59, 28.1%). All participating patients (n= 20, 100%) reported that they had experienced a subjective benefit from MRRT (Figure 1). Furthermore, 85% (n=17) reported an increased patient-perceived benefit from radiotherapy during increasing numbers of radiotherapy courses and negated